![Pinterest](https://pinterest.com/pin/create/button/?url=https://uknews.evprotec.com/revolutionary-alzheimers-drug-can-stop-symptoms/&media=https://uknews.evprotec.com/wp-content/uploads/2023/08/0_Sad-senior-old-woman-Lonely-from-loss-or-sick-with-headache-Upset-patient-in-retirement-home-with.jpg&description=A gene-silencing treatment known as ALN-APP is bringing new hope to Alzheimer's patients after one single dose was proven to reduce levels of amyloid precursor protein by up to 90 per cent A revolutionary drug could offer some hope to Alzheimer's sufferers as it has been proven to alleviate symptoms and prevent further damage in people's brains. The new treatment - currently known as ALN-APP - dials down the gene that produces the proteins that cause Alzheimer's. The results of a phase one trial of the drug, which were published at a medical conference in Amsterdam last month, suggest that a single dose of the drug can reduce levels of amyloid precursor protein by up to 90 per cent. The test, which involved 20 patients, four of whom were in the UK, also showed that levels of the protein were still around 65 per cent lower after six months. The protein is responsible for clumping into the toxic sticky plaques in the brain, causing memory loss associated with Alzheimer's. Scientists now believe that if given early enough, the new drug could stop patients from developing symptoms of Alzheimer's by stopping the process at its source. The trial came after two other drugs - lecanemab and donanemab - were found to show down the root cause of Alzheimer's, reducing cognitive decline by between a quarter and a third. However, the difference between those drugs and the new gene-silencing approach is that the latter stops the proteins from being produced in the first place, explained Dr Catherine Mummery, consultant neurologist at University College London Hospitals, who is leading the UK arm of the trial. She said: "If you're just mopping up the proteins that are already there, you've got to constantly clear the damage while the tap is still on. But if you turn off the tap, you've got a much better chance of preventing further damage." After proving that a single dose reduces protein protection, the team will now expand the trial by giving repeated doses to see if levels can b){kind=link}
A gene-silencing treatment known as ALN-APP is bringing new hope to Alzheimer’s patients after one single dose was proven to reduce levels of amyloid precursor protein by up to 90 per cent
A revolutionary drug could offer some hope to Alzheimer’s sufferers as it has been proven to alleviate symptoms and prevent further damage in people’s brains.
The new treatment – currently known as ALN-APP – dials down the gene that produces the proteins that cause Alzheimer’s. The results of a phase one trial of the drug, which were published at a medical conference in Amsterdam last month, suggest that a single dose of the drug can reduce levels of amyloid precursor protein by up to 90 per cent.
The test, which involved 20 patients, four of whom were in the UK, also showed that levels of the protein were still around 65 per cent lower after six months. The protein is responsible for clumping into the toxic sticky plaques in the brain, causing memory loss associated with Alzheimer’s.
Scientists now believe that if given early enough, the new drug could stop patients from developing symptoms of Alzheimer’s by stopping the process at its source. The trial came after two other drugs – lecanemab and donanemab – were found to show down the root cause of Alzheimer’s, reducing cognitive decline by between a quarter and a third.